The Treatment Section continues to investigate predictors that might be useful for patient-treatment matching to improve the delivery of appropriate treatments to individual patients. In a recently completed project, we conducted a retrospective analysis of data from two randomized clinical trials to test the hypothesis that pre-treatment benzodiazepine use as reported on the Addiction Severity Index (ASI), a widely used clinical interview, would predict treatment outcome. Upon enrollment in methadone maintenance therapy, 361 cocaine/opiate users were randomly assigned to 12-week voucher- or prize-based contingency management or control interventions. The relationship between pre-treatment illicit benzodiazepine use (days of use in the last 30) assessed on ASI prior to initiating treatment and outcome on a range of outcome measures was analyzed. Outcome measures were: urine drug screens; quality of life and self-reported HIV-risk behaviors; and current DSM-IV diagnosis of cocaine and heroin dependence at the end of treatment. In the group receiving contingency management, participants who had reported one or more days of benzodiazepine use pre-treatment had significantly worse outcomes on in-treatment cocaine use, quality-of-life scores, needle-sharing behaviors, and current heroin dependence diagnoses at study exit compared to those who reported no use. In the control group, benzodiazepine users had significantly higher in-treatment cocaine use but did not differ from non-users on psychosocial measures. Thus, in a sample of non-dependent benzodiazepine users, self-reported illicit benzodiazepine use on the ASI, even at low levels, predicted worse outcome on cocaine use and blunted response to contingency management. These findings suggest that benzodiazepine users, even those with relatively modest benzodiazepine use, represent high-need, treatment-resistant patients. Benzodiazepine users in methadone maintenance may benefit from more intensive psychosocial interventions as alternatives, supplements, or prerequisites to contingency management targeted at other drug use. Such interventions could include individualized case management and need-service matching. The utility of these findings is increased by the fact that they were based on self-reported benzodiazepine use collected using the ASI, an assessment tool widely used in both community and research treatment programs.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Intramural Research (Z01)
Project #
1Z01DA000234-16
Application #
7733780
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
16
Fiscal Year
2008
Total Cost
$511,384
Indirect Cost
Name
National Institute on Drug Abuse
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Kowalczyk, William J (2017) The utility of geographically-explicit ecological momentary assessment: from description to intervention. Soc Psychiatry Psychiatr Epidemiol 52:131-133
Ghitza, Udi E; Epstein, David H; Preston, Kenzie L (2008) Self-report of illicit benzodiazepine use on the Addiction Severity Index predicts treatment outcome. Drug Alcohol Depend 97:150-7
Ghitza, Udi E; Epstein, David H; Preston, Kenzie L (2007) Psychosocial functioning and cocaine use during treatment: strength of relationship depends on type of urine-testing method. Drug Alcohol Depend 91:169-77
Heinz, Adrienne; Epstein, David H; Preston, Kenzie L (2007) Spiritual/Religious experiences and in-treatment outcome in an inner-city program for heroin and cocaine dependence. J Psychoactive Drugs 39:41-9
Ghitza, Udi E; Epstein, David H; Preston, Kenzie L (2007) Nonreporting of cannabis use: Predictors and relationship to treatment outcome in methadone maintained patients. Addict Behav 32:938-49
Carroll, C Patrick; Walsh, Sharon L; Bigelow, George E et al. (2006) Assessment of agonist and antagonist effects of tramadol in opioid-dependent humans. Exp Clin Psychopharmacol 14:109-20
Epstein, David H; Preston, Kenzie L; Jasinski, Donald R (2006) Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biol Psychol 73:90-9
Heinz, Adrienne J; Epstein, David H; Schroeder, Jennifer R et al. (2006) Heroin and cocaine craving and use during treatment: measurement validation and potential relationships. J Subst Abuse Treat 31:355-64
Schroeder, Jennifer R; Epstein, David H; Umbricht, Annie et al. (2006) Changes in HIV risk behaviors among patients receiving combined pharmacological and behavioral interventions for heroin and cocaine dependence. Addict Behav 31:868-79
Schroeder, Jennifer R; Schmittner, John P; Epstein, David H et al. (2005) Adverse events among patients in a behavioral treatment trial for heroin and cocaine dependence: effects of age, race, and gender. Drug Alcohol Depend 80:45-51

Showing the most recent 10 out of 32 publications